Get the Stockscreener App
47.70
5.60%
2.53
After Hours:
47.70
Vera Therapeutics Inc stock is traded at $47.70, with a volume of 846.00K.
It is up +5.60% in the last 24 hours and up +16.80% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$45.17
Open:
$45.24
24h Volume:
846.00K
Relative Volume:
1.29
Market Cap:
$2.96B
Revenue:
-
Net Income/Loss:
$-94.30M
P/E Ratio:
-14.20
EPS:
-3.36
Net Cash Flow:
$-99.72M
1W Performance:
+11.01%
1M Performance:
+16.80%
6M Performance:
+9.81%
1Y Performance:
+353.42%
1-Day Range:
$44.94
$48.00
1-Week Range:
$40.27
$48.00
52-Week Range:
$9.88
$50.78
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
8000 MARINA BOULEVARD, SUITE 120, BRISBANE
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics (NASDAQ:VERA) Given New $75.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Vera Therapeutics (NASDAQ:VERA) Shares Up 7.3%Here's Why - MarketBeat
Vera Therapeutics announces proposed public offering of class A common stock - MSN
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 - Investing.com India
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Vera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at Guggenheim - Defense World
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownHere's Why - MarketBeat
Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Yahoo Finance
SEC Form 424B5 filed by Vera Therapeutics Inc. - Quantisnow
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewswire Inc.
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00 - MarketBeat
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - AOL
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's What Happened - MarketBeat
Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study - MarketWatch
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
Vera reports long-term atacicept data at Kidney Week 2024 - The Pharma Letter
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - The Manila Times
Vera Therapeutics Announces 96-week eGFR Stabilization in - GlobeNewswire
Marshall Fordyce Sells 19,375 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock - MarketBeat
Vera Therapeutics CEO sells shares worth $782,610 By Investing.com - Investing.com South Africa
Vera Therapeutics CEO sells shares worth $782,610 - Investing.com
Trend Tracker for (VERA) - Stock Traders Daily
Markel Corp (MKL-N) QuotePress Release - The Globe and Mail
Eastern Bank Purchases Shares of 56,050 Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail
Polycythemia Vera Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials | Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therapeutics, Ascentage - The Globe and Mail
Vera Therapeutics (NASDAQ:VERA) Coverage Initiated by Analysts at Scotiabank - MarketBeat
A year in review: Vera Therapeutics Inc (VERA)’s performance in the last year - US Post News
The Potential Rise in the Price of Vera Therapeutics Inc (VERA) following insiders activity - Knox Daily
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Vera Therapeutics CEO sells shares worth over $597k - Investing.com India
Vera Therapeutics CEO sells shares worth over $597k By Investing.com - Investing.com South Africa
Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $597,500.00 in Stock - MarketBeat
Nonfat Dry Milk (DFU25) Quote - The Globe and Mail
Vera Therapeutics Inc [VERA] Stock sold by Insider Fordyce Marshall for $1.06 million - Knox Daily
It would be worthwhile to take a closer look at Vera Therapeutics Inc (VERA) - US Post News
Analytical Lens: Exploring Vera Therapeutics Inc (VERA)’s Financial Story Through Ratios - The Dwinnex
The Manufacturers Life Insurance Company Raises Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
TD Cowen sticks with buy rating on Vera Therapeutics, confident in upcoming clinical data - Investing.com Canada
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients (NASDAQ:VERA) - Seeking Alpha
VERA Stock Sees Decline of Approximately -7.06% in Last Five Days - Knox Daily
Point72 Asset Management L.P. Sells 1,056,148 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics to present atacicept trial results at Kidney Week By Investing.com - Investing.com South Africa
Vera broadens atacicept study to more kidney diseases By Investing.com - Investing.com South Africa
Vera broadens atacicept study to more kidney diseases - Investing.com
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):